Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer
Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer
Sentinel Node Disection No Worse Than Axillary
Triple-Negative Breast Cancer Equally Aggressive in Whites
RG7204 Meets Endpoints Of Extending Survival, PFS
INSPIRE Enrollment Stopped; Thromboembolism Risk Cited
Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone
mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients
Afinitor Tablet Doubles PFS; Lowers Progression Risk 65%
Study Links Native American Ancestry to Leukemia Relapse
Study Explores Reasons Women Avoid Mammograms
Hormone Therapy At Menopause Linked to More Breast Cancer Risk
Children of Male Cancer Survivors Have Highrt Risk of Birth Defects
Study Finds No Link Between Tumor Grade and Relapse Risk
Clinical Trials Approved By NCI CTEP Last Month
Rituxan Approved as Maintenance For Advanced Follicular Lymphoma
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Jonathan Licht named president, chief scientific officer at Van Andel Institute
- Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Duke brain cancer researcher Kyle Walsh named director of NIEHS
